<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosntds</journal-id><journal-title-group>
<journal-title>PLoS Neglected Tropical Diseases</journal-title></journal-title-group>
<issn pub-type="epub">1935-2735</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PNTD-D-13-01395</article-id>
<article-id pub-id-type="doi">10.1371/journal.pntd.0002667</article-id>
    <article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine and health sciences</subject><subj-group><subject>Infectious diseases</subject><subj-group><subject>Fungal diseases</subject><subj-group><subject>Mycetoma</subject></subj-group></subj-group></subj-group><subj-group><subject>Tropical diseases</subject><subj-group><subject>Neglected tropical diseases</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>The Mycetoma Knowledge Gap: Identification of Research Priorities</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>van de Sande</surname><given-names>Wendy W. J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Maghoub</surname><given-names>El Sheikh</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fahal</surname><given-names>Ahmed H.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Goodfellow</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Welsh</surname><given-names>Oliverio</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Zijlstra</surname><given-names>Ed</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib>
</contrib-group>
<aff id="aff1"><label>1</label><addr-line>ErasmusMC, Department of Medical Microbiology and Infectious Diseases, Rotterdam, The Netherlands</addr-line></aff>
<aff id="aff2"><label>2</label><addr-line>Mycetoma Research Centre, University of Khartoum, Khartoum, Sudan</addr-line></aff>
<aff id="aff3"><label>3</label><addr-line>School of Biology, University of Newcastle, Newcastle upon Tyne, United Kingdom</addr-line></aff>
<aff id="aff4"><label>4</label><addr-line>Dr. Jose E. Gonzalez University Hospital, Universidad Autónoma de Nuevo León, Department of Dermatology, Ave Madero y Ave Gonzalitos, Colonia Mitras Centro, Monterrey, Nuevo Leon, Mexico</addr-line></aff>
<aff id="aff5"><label>5</label><addr-line>Rotterdam Centre for Tropical Medicine, Rotterdam, The Netherlands</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Wanke</surname><given-names>Bodo</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><addr-line>Fundação Oswaldo Cruz, Brazil, United States of America</addr-line></aff>
<author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">w.vandesande@erasmusmc.nl</email></corresp>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn>
</author-notes>
<pub-date pub-type="collection"><month>3</month><year>2014</year></pub-date>
<pub-date pub-type="epub"><day>27</day><month>3</month><year>2014</year></pub-date>
<volume>8</volume>
<issue>3</issue>
<elocation-id>e2667</elocation-id><permissions>
<copyright-year>2014</copyright-year>
<copyright-holder>van de Sande et al</copyright-holder><license xlink:type="simple"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions>
<abstract>
<p>Mycetoma is a tropical disease which is caused by a taxonomically diverse range of actinomycetes (actinomycetoma) and fungi (eumycetoma). The disease was only recently listed by the World Health Organization (WHO) as a neglected tropical disease (NTD). This recognition is the direct result of a meeting held in Geneva on February 1, 2013, in which experts on the disease from around the world met to identify the key research priorities needed to combat mycetoma. The areas that need to be addressed are highlighted here. The initial priority is to establish the incidence and prevalence of the disease in regions where mycetoma is endemic, prior to determining the primary reservoirs of the predominant causal agents and their mode of transmission to susceptible individuals in order to establish novel interventions that will reduce the impact of the disease on individuals, families, and communities. Critically, economical, reliable, and effective methods are required to achieve early diagnosis of infections and consequential improved therapeutic outcomes. Molecular techniques and serological assays were considered the most promising in the development of novel diagnostic tools to be used in endemic settings. Improved strategies for treating eumycetoma and actinomycetoma are also considered.</p>
</abstract>
<funding-group><funding-statement>The authors have indicated that no specific funding was received for this work.</funding-statement></funding-group><counts><page-count count="7"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>Currently there are 17 infections listed by the World Health Organization as neglected tropical diseases and three others are cited as neglected conditions <xref ref-type="bibr" rid="pntd.0002667-WHO1">[1]</xref>. Until July 2013, mycetoma was absent from the WHO list, even though its estimated prevalence of two per 100,000 inhabitants was comparable to that of other recognized neglected diseases, such as Buruli ulcer and Human African trypanosomiasis <xref ref-type="bibr" rid="pntd.0002667-Merritt1">[2]</xref>, <xref ref-type="bibr" rid="pntd.0002667-VandeSande1">[3]</xref>.</p>
<p>Mycetoma is an implantation mycosis <xref ref-type="bibr" rid="pntd.0002667-QueirozTelles1">[4]</xref>, characterized by large tumor-like swellings and located mainly in the extremities. It can be caused by taxonomically diverse microorganisms, both of bacterial (actinomycetoma) and fungal origin (eumycetoma) <xref ref-type="bibr" rid="pntd.0002667-Ahmed1">[5]</xref>. The most common causative agents include the fungus <italic>Madurella mycetomatis</italic> and the actinomycetes <italic>Nocardia brasiliensis, Actinomadura madurae, Streptomyces somaliensis</italic>, and <italic>Actinomadura pelletieri</italic> <xref ref-type="bibr" rid="pntd.0002667-VandeSande1">[3]</xref>. The disease is mainly found in tropical and subtropical regions of the world, and the majority of patients are reported from Mexico, Senegal, Sudan, and India, but its true prevalence and incidence are not well defined <xref ref-type="bibr" rid="pntd.0002667-VandeSande1">[3]</xref>. Furthermore, there are no rapid diagnostic tools, while treatment, especially for eumycetoma, is unsatisfactory, resulting in high morbidity, including amputation of limbs (submitted; see Acknowledgments).</p>
<p>On February 1, 2013, a landmark meeting was held in Geneva, Switzerland that was attended by experts on mycetoma from around the world. Its aim was to review all currently available information and to identify knowledge gaps and research priorities. It was concluded that basic epidemiological information is lacking: it is not known how many people are suffering from mycetoma or where the disease is most prevalent. Furthermore, early detection of mycetoma is difficult, while treatment is far from satisfactory for eumycetoma patients.</p>
<p>In this paper, we consider the knowledge gaps and research priorities identified at the Geneva meeting.</p>
</sec><sec id="s2">
<title>Epidemiology</title>
<sec id="s2a">
<title>The incidence, prevalence, and mapping of mycetoma</title>
<p>Although mycetoma was first introduced to modern science in 1694 by Kaempfer in his dissertation <xref ref-type="bibr" rid="pntd.0002667-Kaempfer1">[6]</xref>, it is still not known how many people are affected by this disease. In order to get a rough estimation on the global burden of mycetoma, van de Sande performed a meta-analysis in which 8,763 cases were reviewed <xref ref-type="bibr" rid="pntd.0002667-VandeSande1">[3]</xref>. These cases were from various countries, including India, Mexico, Niger, and Sudan <xref ref-type="bibr" rid="pntd.0002667-Fahal1">[7]</xref>–<xref ref-type="bibr" rid="pntd.0002667-Buot1">[16]</xref>. By dividing the number of reported cases by the country population in each year, an estimate of the prevalence per country was calculated. The estimated prevalence ranged from 3.49 cases per 100,000 inhabitants in Mauritania to &lt;0.01 cases per 100,000 inhabitants in many other countries <xref ref-type="bibr" rid="pntd.0002667-VandeSande1">[3]</xref>. The estimated prevalence for the endemic areas of mycetoma, Mexico and Sudan, were 0.15 and 1.81 cases per 100,000 inhabitants, respectively. Although this study gave insight into the prevalence of mycetoma, the estimates do not reflect the magnitude of the problem. The total number of patients is probably much higher, since the prevalence was mainly derived from single-center studies, and large epidemiological studies from a number of countries in which mycetoma is known to exist, such as South Africa, are lacking <xref ref-type="bibr" rid="pntd.0002667-VandeSande1">[3]</xref>, <xref ref-type="bibr" rid="pntd.0002667-Culligan1">[17]</xref>–<xref ref-type="bibr" rid="pntd.0002667-Vismer1">[19]</xref>. Furthermore, at the Mycetoma Research Centre in Khartoum, more than 6,400 patients have been seen and treated, but this has not been reported in the literature (Fahal, in preparation). Surveys performed in mycetoma-endemic villages in Sudan suggest a prevalence ranging from 0–8.5 per 1,000 inhabitants (<xref ref-type="table" rid="pntd-0002667-t001">Table 1</xref>) <xref ref-type="bibr" rid="pntd.0002667-Murray1">[20]</xref>, <xref ref-type="bibr" rid="pntd.0002667-The1">[21]</xref>.</p>
<table-wrap id="pntd-0002667-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0002667.t001</object-id><label>Table 1</label><caption>
<title>Prevalence of mycetoma as reported in Sudanese villages.<xref ref-type="table-fn" rid="nt101">*</xref></title>
</caption><alternatives><graphic id="pntd-0002667-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pntd.0002667.t001" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Village</td>
<td align="left" rowspan="1" colspan="1">Year</td>
<td align="left" rowspan="1" colspan="1">Population</td>
<td align="left" rowspan="1" colspan="1">Number of cases</td>
<td align="left" rowspan="1" colspan="1">Prevalence per 1,000</td>
<td align="left" rowspan="1" colspan="1">Reference</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Abu Gumri</td>
<td align="left" rowspan="1" colspan="1">1960</td>
<td align="left" rowspan="1" colspan="1">1,300</td>
<td align="left" rowspan="1" colspan="1">8</td>
<td align="left" rowspan="1" colspan="1">6.2</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pntd.0002667-Murray1">[20]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">El Andalous</td>
<td align="left" rowspan="1" colspan="1">2011</td>
<td align="left" rowspan="1" colspan="1">2,835</td>
<td align="left" rowspan="1" colspan="1">24</td>
<td align="left" rowspan="1" colspan="1">8.5</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pntd.0002667-The1">[21]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Arkawit</td>
<td align="left" rowspan="1" colspan="1">1960</td>
<td align="left" rowspan="1" colspan="1">56</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pntd.0002667-Murray1">[20]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Beriab</td>
<td align="left" rowspan="1" colspan="1">1960</td>
<td align="left" rowspan="1" colspan="1">1,350</td>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">5.2</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pntd.0002667-Murray1">[20]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Denegila</td>
<td align="left" rowspan="1" colspan="1">1960</td>
<td align="left" rowspan="1" colspan="1">1,025</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">1.0</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pntd.0002667-Murray1">[20]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Rabua</td>
<td align="left" rowspan="1" colspan="1">1960</td>
<td align="left" rowspan="1" colspan="1">500</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">2.0</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pntd.0002667-Murray1">[20]</xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Seraam</td>
<td align="left" rowspan="1" colspan="1">1960</td>
<td align="left" rowspan="1" colspan="1">500</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="pntd.0002667-Murray1">[20]</xref></td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt101"><label/><p>*Data obtained mainly from <xref ref-type="bibr" rid="pntd.0002667-Murray1">[20]</xref>.</p></fn></table-wrap-foot></table-wrap>
<p>It can be concluded from the current situation that (inter)national surveillance programs are needed to get a reliable indication of the prevalence of mycetoma. In the first instance, this could be achieved by using a surveillance form similar to the BU02 (<ext-link ext-link-type="uri" xlink:href="http://www.who.int/buruli/control/ENG_BU_02.pdf" xlink:type="simple">http://www.who.int/buruli/control/ENG_BU_02.pdf</ext-link>), which is used for Buruli ulcer <xref ref-type="bibr" rid="pntd.0002667-VandeSande1">[3]</xref>. The BU02 form is used to establish the prevalence of Buruli ulcer in different districts in Cameroon and the Democratic Republic of Congo (DRC). The Akonolinga district in Cameroon and the Songololo territory in DRC were found to have a high prevalence <xref ref-type="bibr" rid="pntd.0002667-Porten1">[22]</xref>, <xref ref-type="bibr" rid="pntd.0002667-Phanzu1">[23]</xref>. Subsequently, Buruli ulcer control projects launched in these two locations resulted in an increase in the number of Buruli cases detected <xref ref-type="bibr" rid="pntd.0002667-Porten1">[22]</xref>,<xref ref-type="bibr" rid="pntd.0002667-Phanzu1">[23]</xref>. As a result, there was a significant increase in the proportion of early lesions and simple ulcerative forms and a decrease in the proportion of relapse cases <xref ref-type="bibr" rid="pntd.0002667-Phanzu1">[23]</xref>. These results indicate that defining areas with a high prevalence and establishing informed local health institutes reduces the burden of disease. The application of a similar approach for mycetoma, including the use of standardized forms and the establishment of national reference centers, can be expected to generate more reliable data on the incidence and prevalence of mycetoma. In Sudan, part of the infrastructure and data needed are already available. A national Mycetoma Research Centre is situated in the capital, Khartoum. Furthermore, in 1956, Abbott already demonstrated that in Atbara, Ed Dueim, and Wad Medani the prevalence among hospital admissions was higher than in the capital (prevalence 9.2, 9.3, and 11.8 per 1,000 hospital admissions, respectively, versus 5.1 in Khartoum) <xref ref-type="bibr" rid="pntd.0002667-Abbott1">[8]</xref>. The distance from these cities to Khartoum ranges from 190 km to 328 km, making the trip to the Mycetoma Research Centre difficult and expensive. The late presentation to the clinic is attributed to the nature of mycetoma, which is usually painless and slowly progressive, and the lack of health education. Furthermore, since most of the patients are of low socioeconomic status, financial constraints also play an important role. Therefore, more patients will be reached when regional health centers with healthcare personnel trained in the disease are established in highly endemic regions. The need was partially realized in October 2012 when a new Mycetoma center was opened in Wad Medani <xref ref-type="bibr" rid="pntd.0002667-BNNICD1">[24]</xref>. However, more satellite centers are needed in a country as large as Sudan. Better incidence and prevalence data are necessary to determine appropriate sites for new mycetoma institutes in the Sudan and other mycetoma regions, including India, Mexico, and Senegal.</p>
</sec></sec><sec id="s3">
<title>The Mode of Transmission</title>
<p>Other information which is lacking is how people become infected with the causative agents of mycetoma. The primary reservoir of the causal agents is believed to be soil. Among the actinomycetes, <italic>A. madurae</italic> <xref ref-type="bibr" rid="pntd.0002667-Segretain1">[25]</xref>, <italic>A. pelletieri</italic> <xref ref-type="bibr" rid="pntd.0002667-Segretain1">[25]</xref>, <italic>N. asteroides</italic> <xref ref-type="bibr" rid="pntd.0002667-Segretain1">[25]</xref>–<xref ref-type="bibr" rid="pntd.0002667-Orchard1">[27]</xref>, <italic>N. brasiliensis</italic> <xref ref-type="bibr" rid="pntd.0002667-Segretain1">[25]</xref>, <xref ref-type="bibr" rid="pntd.0002667-GonzalezOchoa1">[28]</xref>, <italic>S. somalienis</italic> <xref ref-type="bibr" rid="pntd.0002667-Segretain1">[25]</xref>, <xref ref-type="bibr" rid="pntd.0002667-Parthasarathi1">[26]</xref>, and among the fungi, <italic>Falciformispora senegalensis</italic> (previously known as <italic>Leptosphaeria senegalensis</italic>) <xref ref-type="bibr" rid="pntd.0002667-Segretain1">[25]</xref>, <italic>M. mycetomatis</italic> <xref ref-type="bibr" rid="pntd.0002667-Thirumalachar1">[29]</xref>, <italic>Neotestudina rosatii</italic> <xref ref-type="bibr" rid="pntd.0002667-Segretain1">[25]</xref> and <italic>Scedosporium boydii</italic> <xref ref-type="bibr" rid="pntd.0002667-Sotgiu1">[30]</xref>–<xref ref-type="bibr" rid="pntd.0002667-Ajello2">[32]</xref> have been cultured from soil, though in many cases it is difficult to be certain that strains have been correctly identified, especially since they tend not to have been properly preserved. Several recent attempts to culture the fungus <italic>M. mycetomatis</italic> from soil have failed, although DNA of the organism was detected in 17 out of 74 soil samples and in one out of 22 thorn samples <xref ref-type="bibr" rid="pntd.0002667-Ahmed2">[33]</xref>. There is now evidence based on phylogenetic analyses that <italic>M. mycetomatis</italic> may be closely related to dung-inhabiting fungi, suggesting that its primary reservoir could overlap with the natural niche of these fungi <xref ref-type="bibr" rid="pntd.0002667-deHoog1">[34]</xref>. Another mycetoma-causative agent, <italic>N. asteroides</italic>, has been isolated from cow dung in India <xref ref-type="bibr" rid="pntd.0002667-Parthasarathi1">[26]</xref>. More studies are needed to establish the environmental niches of the mycetoma causative agents and their mode of transmission to patients (<xref ref-type="fig" rid="pntd-0002667-g001">Figure 1</xref>).</p>
<fig id="pntd-0002667-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0002667.g001</object-id><label>Figure 1</label><caption>
<title>Possible hypothesis for mycetoma infection route.</title>
<p>At the moment, many questions still remain about the various steps in the development of mycetoma. First, it is not known where the causative agents reside. What is the natural habitat of these agents? Both soil and dung have been implicated, but other niches could also be involved. Second, how is the causative agent introduced into the subcutaneous tissue? Is it via a thorn prick as implicated for years, or are vectors, such as insects, involved? When the causative agent is introduced in the subcutaneous tissue, will it always cause mycetoma, or does the host play a role as well? Do immune status, genetic background, or co-infections play a role in the development of mycetoma or even the extent of the infection?</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pntd.0002667.g001" position="float" xlink:type="simple"/></fig>
<p>Irrespective of the natural niche of the causative agent, it has to reach the subcutaneous tissue in order to cause mycetoma. Historically, this disease has been associated with minor trauma caused by thorn pricks, stones, or snake and insect bites <xref ref-type="bibr" rid="pntd.0002667-Fahal2">[35]</xref>. Also, how the grain itself forms has not been studied. Some studies have focused on the components of the grain but the formation itself is not understood <xref ref-type="bibr" rid="pntd.0002667-Findlay1">[36]</xref>–<xref ref-type="bibr" rid="pntd.0002667-Ibrahim1">[39]</xref>. The detection of remnants of thorns inside lesions of mycetoma patients has given credence to the importance of thorns <xref ref-type="bibr" rid="pntd.0002667-Fahal2">[35]</xref>, especially since thorns are abundant in mycetoma-endemic regions. <italic>F. senegalensis</italic> and <italic>Medicopsis romeroi</italic> (previously known as <italic>Pyrenochaeta romeroi</italic>) have been isolated from thorns <xref ref-type="bibr" rid="pntd.0002667-Fahal2">[35]</xref>. However, thorn pricks are also common in people who do not develop mycetoma, a result which suggests that other factors may be important and/or that the immune system has a role in the disease process.</p>
<p>The role of the immune system in mycetoma patients has been studied to some extent <xref ref-type="bibr" rid="pntd.0002667-Mahgoub1">[40]</xref>–<xref ref-type="bibr" rid="pntd.0002667-MendezTovar1">[43]</xref>. It would seem that there are no obvious defects in the immune system, but some single nucleotide polymorphisms have been linked with mycetoma development <xref ref-type="bibr" rid="pntd.0002667-vandeSande1">[41]</xref>, <xref ref-type="bibr" rid="pntd.0002667-Mhmoud1">[42]</xref>. Furthermore, from animal experiments it appears that a Th2-response might be necessary to induce mycetoma <xref ref-type="bibr" rid="pntd.0002667-Cavanagh1">[44]</xref>–<xref ref-type="bibr" rid="pntd.0002667-Mahgoub2">[46]</xref>. Recently it was demonstrated that a co-infection with schistosomiasis, a strong Th2-inducer, was linked to mycetoma susceptibility <xref ref-type="bibr" rid="pntd.0002667-vanHellemond1">[47]</xref>. The role of animals should be investigated in endemic areas where people live in close contact with animals (cattle, donkeys, dogs, sheep, chicken, etc.) that are kept in compounds and where the ground is covered with animal dung. The role of animal reservoirs has been shown to be important in the development of many other (subcutaneous) infections, as exemplified by plague <xref ref-type="bibr" rid="pntd.0002667-Prentice1">[48]</xref>, schistosomiasis <xref ref-type="bibr" rid="pntd.0002667-Gryseels1">[49]</xref>, Lyme disease <xref ref-type="bibr" rid="pntd.0002667-Radolf1">[50]</xref>, and leishmaniaisis <xref ref-type="bibr" rid="pntd.0002667-Kweku1">[51]</xref>. For mycetoma, intermediate hosts have not been detected, though, interestingly, <italic>N. asteroides, N. otidiscaviarum</italic>, and <italic>S. somaliensis</italic> have been isolated from the gut and casts of four different earthworm species <xref ref-type="bibr" rid="pntd.0002667-Parthasarathi1">[26]</xref>.</p>
<p>Identifying the primary reservoir and the route of infection could help in developing control strategies to prevent transmission of the causative agent to the subcutaneous tissue (<xref ref-type="fig" rid="pntd-0002667-g001">Figure 1</xref>). Examples of such control measurements for other infectious diseases are numerous, ranging from mass drug administration to combat schistosomiasis <xref ref-type="bibr" rid="pntd.0002667-Zhang1">[52]</xref> to distributing bed nets for the control of malaria <xref ref-type="bibr" rid="pntd.0002667-Curtis1">[53]</xref>. The identification of risk factors associated with the development of mycetoma could provide clues to the natural route of infection. Epidemiological screening and culturing of causative agents from habitats in endemic regions is needed to answer these questions and plan effective controls. Easy interventions such as the distribution of closed shoes, removal of cattle and other animals from the compound, or clearing thorny bushes from the compound's immediate surroundings could possibly prevent mycetoma.</p>
</sec><sec id="s4" sec-type="methods">
<title>Development of Methods for Early Diagnosis</title>
<p>In order to be able to determine the true burden of mycetoma and to identify the primary reservoir(s) and potential intermediate host(s) of its causative agents, good, reliable, fast, and cheap diagnostic tools are needed. At present, it is very difficult to reliably discriminate between infected and noninfected individuals in the field (submitted; see Acknowledgments); early cases without lesions are almost impossible to identify since they don't show classical signs of mycetoma and grains are still absent. The available diagnostic tools include imaging to determine the extent of lesions along different tissue planes, and cytological, histopathological examinations and culturing of grains to identify the causative agent (submitted; see Acknowledgments). Deep surgical biopsy material is needed for the latter two procedures. Identification of causal agents to the species level with histology is next to impossible, while culturing them is difficult and time-consuming, especially for nonsporulating fungi (submitted; see Acknowledgments). Misidentification of causal agents in the past has caused poor therapeutic outcomes <xref ref-type="bibr" rid="pntd.0002667-Mhmoud2">[54]</xref>. More reliable diagnostic techniques depending on DNA analysis have been developed for the detection of actinobacterial and fungal causal agents, but such approaches are too expensive for use in endemic areas at the present time <xref ref-type="bibr" rid="pntd.0002667-Ahmed4">[55]</xref>, <xref ref-type="bibr" rid="pntd.0002667-Quintana1">[56]</xref>. Therefore, one of the first priorities is to develop fast and reliable diagnostic tools which can be used as point-of-care tests in regions where mycetoma is endemic. Since it has been demonstrated that 65% of all mycetoma cases can be attributed to <italic>M. mycetomatis, N. brasiliensis, A. madurae, A. pelletieri, N. asteroides</italic>, and <italic>S. somaliensis</italic>, the initial focus should be on the identification of these causative agents. Diagnostic methods which are most applicable are DNA-based identification tools such as loop-mediated isothermal amplification (LAMP), and serological assays.</p>
<p>LAMP has been successfully used in Africa and India <xref ref-type="bibr" rid="pntd.0002667-Namangala1">[57]</xref>–<xref ref-type="bibr" rid="pntd.0002667-Surabattula1">[59]</xref> to diagnose Human African trypanosomiasis (HAT), malaria and visceral leishmaniasis. Sufficient DNA can be isolated from a dried blood spot on Whatman filter paper using simple extraction methods <xref ref-type="bibr" rid="pntd.0002667-Matovu1">[58]</xref>–<xref ref-type="bibr" rid="pntd.0002667-Verma1">[60]</xref>. For the detection of Buruli ulcer, swabs or fine needle aspirates are used <xref ref-type="bibr" rid="pntd.0002667-Ablordey1">[61]</xref>. Isolated DNA can be amplified by using a heating bath and the resulting amplicons are usually visualized by adding (fluorescent) dyes <xref ref-type="bibr" rid="pntd.0002667-Namangala1">[57]</xref>–<xref ref-type="bibr" rid="pntd.0002667-Ablordey1">[61]</xref>. This technique might be adapted for mycetoma, and various patient samples, including blood, serum, or fine needle aspirates, can be tested to determine the specificity and sensitivity of this assay in mycetoma patients.</p>
<p>Other diagnostic tools applicable in endemic settings are serological-based procedures, such as latex bead agglutination assays and dipsticks. By binding either an antigen <xref ref-type="bibr" rid="pntd.0002667-Akhoundi1">[62]</xref>, <xref ref-type="bibr" rid="pntd.0002667-SilveiraGomes1">[63]</xref> or a specific antibody <xref ref-type="bibr" rid="pntd.0002667-Attar1">[64]</xref>, <xref ref-type="bibr" rid="pntd.0002667-Darani1">[65]</xref> of the causative agent to a latex bead, a cheap and fast screening tool for serum can be developed that minimally requires the use of any equipment. Latex bead assays have been developed for other tropical infections, including visceral leismaniasis <xref ref-type="bibr" rid="pntd.0002667-Akhoundi1">[62]</xref>, <xref ref-type="bibr" rid="pntd.0002667-Attar1">[64]</xref> and paracoccidioidomycosis <xref ref-type="bibr" rid="pntd.0002667-SilveiraGomes1">[63]</xref>. In order to develop a specific agglutination assay, a discriminatory antigen needs to be selected. Whole genomes are available for <italic>N. brasiliensis</italic> <xref ref-type="bibr" rid="pntd.0002667-Prentice1">[48]</xref> and <italic>S. somaliensis</italic> <xref ref-type="bibr" rid="pntd.0002667-vanHellemond1">[47]</xref>, while those of other causal agents such as <italic>M. mycetomatis</italic> and <italic>S. sudanensis</italic> are being generated. The genomes of these species will be ideal resources to select specific proteins for rapid serodiagnosis.</p>
</sec><sec id="s5">
<title>Treatment</title>
<p>Accurate diagnosis of the causal agents of mycetoma is a prerequisite for proper treatment. The current therapy includes medical treatment or a combination of medical treatment and surgery. Prevention by vaccination is not presently available. Mining the genomes of the most common causative agents could identify potential vaccine candidates. Currently, actinomycetoma is treated with antibacterials. The most common drug treatment for uncomplicated cases is trimethoprim-sulfamethoxazole (TMP-SMX) given for several months until cure is achieved <xref ref-type="bibr" rid="pntd.0002667-Welsh1">[66]</xref>, <xref ref-type="bibr" rid="pntd.0002667-Zein1">[67]</xref>. A study in the 1970s by Mahgoub evaluated several antimicrobial combinations in 144 patients with actinomycetoma. In this study, the best clinical outcome was obtained with sulfamethoxazole plus streptomycin. This resulted in the following clinical outcomes: 63.2% cured, 21.5% greatly improved, and 11.1% showing some improvement <xref ref-type="bibr" rid="pntd.0002667-Mahgoub3">[68]</xref>. In Sudan, the reported cure rate was 43.3%, excluding patients who did not complete the treatment <xref ref-type="bibr" rid="pntd.0002667-Zein1">[67]</xref>. At present, in Mexico, when there is no therapeutic response or improvement with TMP-SMX, or when the infection is severe and disseminated, or in a special location with a risk of spread to underlying vital tissues (head, neck, trunk, abdomen, or inguinal region), a combination of amikacin (15 mg/kg/day) for 3 weeks plus trimethoprim-sulfamethoxazole (8/40 mg/kg/day) for 5 weeks (a cycle of treatment) is given for up to five cycles. This treatment has achieved a cure rate of &gt;90% <xref ref-type="bibr" rid="pntd.0002667-Welsh1">[66]</xref>.</p>
<p>For eumycetoma, antifungal therapy consists mainly of ketoconazole or itraconazole combined with surgical excision <xref ref-type="bibr" rid="pntd.0002667-Zein1">[67]</xref>. Unfortunately, this therapy is not quite successful. A recent study conducted at the Mycetoma Research Centre in Khartoum, Sudan showed that of the 1,242 eumycetoma patients studied, only 321 (25.9%) were cured, 35 (2.8%) had amputations, and 671 of the patients (54%) dropped out from the outpatient follow-up for various reasons. One of these reasons was the dissatisfaction with the therapy outcome <xref ref-type="bibr" rid="pntd.0002667-Zein1">[67]</xref>. In addition, in Sudan, most patients pay for their treatments. With a monthly income of $60, the costs of a ketoconazole ($30/month) or itraconazole treatment ($330/month) are a severe financial burden on an average household. Furthermore, it has been known to cause important side effects, such as hepatic toxicity, gynaecomastia, and skin discoloration <xref ref-type="bibr" rid="pntd.0002667-Findor1">[69]</xref>, <xref ref-type="bibr" rid="pntd.0002667-Bernuau1">[70]</xref>. Many patients stop therapy and are lost to follow-up in outpatient clinics, only to present later with a massive relapse, often requiring amputation.</p>
<p>For actinomycetoma, 168 out of 302 patients seen in the Mycetoma Research Centre in Khartoum did not complete their treatment. For eumycetoma, the corresponding figures were 671 out of 1,241 patients <xref ref-type="bibr" rid="pntd.0002667-Zein1">[67]</xref>. Therefore, there is an urgent need to develop better antifungal therapy, better treatment strategies, and a shorter treatment regime. A first step in improving therapy has been made by determining the in vitro susceptibilities of the most common fungal causative agent <italic>M. mycetomatis</italic> against a large panel of marketed antifungal agents <xref ref-type="bibr" rid="pntd.0002667-vandeSande2">[71]</xref>–<xref ref-type="bibr" rid="pntd.0002667-Ahmed5">[75]</xref>. <italic>M. mycetomatis</italic> appeared to be most susceptible to the azole class of antifungal agents. Only poor inhibitory concentrations were found for other compounds. There is now a need to link in vitro susceptibility data with clinical outcome. There is also a need to generate minimal inhibitory concentration (MIC) breakpoints for in vitro susceptibility linked to therapeutic susceptibility or resistance.</p>
<p>In order to improve current therapy for <italic>M. mycetomatis</italic> infections, the best approaches are to select safer, newer azoles to which the organism is susceptible or use treatments that combine traditionally used azoles with (newly) available antifungal agents with different targets. Antifungal agents that have been used clinically in the treatment of eumycetoma include ketoconazole <xref ref-type="bibr" rid="pntd.0002667-Mahgoub4">[76]</xref>, itraconazole <xref ref-type="bibr" rid="pntd.0002667-Fahal3">[77]</xref>, posaconazole <xref ref-type="bibr" rid="pntd.0002667-Negroni1">[78]</xref>, voriconazole <xref ref-type="bibr" rid="pntd.0002667-Lacroix1">[79]</xref>–<xref ref-type="bibr" rid="pntd.0002667-Schaenman1">[82]</xref>, and terbinafin <xref ref-type="bibr" rid="pntd.0002667-NDiaye1">[83]</xref>. The association of an azole with terbinafin is the most logical combination to be explored, as these two drugs have a different mode of action. Preliminary data on the use of liposomal amphotericin B are promising in terms of efficacy with good drug penetration (Fahal, personal communication). But since this drug is only available intravenously and is highly expensive, its feasibility in the long term for mycetoma treatment remains questionable. As 65% of patients have a secondary bacterial infection <xref ref-type="bibr" rid="pntd.0002667-Ahmed6">[84]</xref>, the combination of antifungal and antibacterial treatment should be explored.</p>
<p>In addition to the application of new drug therapies for mycetoma, there is a need to shorten treatment times. It is currently difficult to estimate the duration of antibiotic treatment. Based on clinical and radiological criteria, a cure is defined as complete disappearance of the mass, healing of sinuses, skin returned to normal, bone restored to improved radiological appearance, absence of hyper-reflective echoes and cavities on ultrasound examination, and the absence of grains in needle aspirates <xref ref-type="bibr" rid="pntd.0002667-Zein1">[67]</xref>. The radiological improvement consists of remolding, absorption of the sclerotic bone, and reappearance of the normal trabecular pattern as well as bone density. A simple, reliable biomarker for cure is urgently needed to assess the response to treatment.</p>
</sec><sec id="s6">
<title>Conclusion</title>
<p>In order to be able to improve the current management of mycetoma, we have identified knowledge gaps for which research is urgently needed. These include the estimation of the burden of mycetoma in order to focus treatment and care on those locations with the highest prevalence. Furthermore, identification of the natural habitat of causal agents and establishing how they are introduced into subcutaneous tissues could lead to novel interventions, which ultimately will reduce its incidence. The development of methods for early diagnosis and therapeutic monitoring will result in better therapeutic outcomes. Improvement of therapeutic strategies in eumycetoma will also reduce the burden of disease. Now that the key research priorities have been highlighted, it is time to implement them. The WHO has taken an important first step by including mycetoma on the list of NTDs. Further recognition by the international community is needed. Resources need to be made available to design control efforts and improve patient management.</p>
<boxed-text id="pntd-0002667-box001" position="float"><sec id="s6a">
<title>Key Learning Points</title>
<list list-type="bullet"><list-item>
<p>Obtaining better incidence and prevalence data is necessary to determine appropriate sites for erecting mycetoma health care facilities.</p>
</list-item><list-item>
<p>Gaining insight into the natural habitat and the mode of transmission of the mycetoma causative agents will open the door to preventive measures to reduce the number of mycetoma cases worldwide.</p>
</list-item><list-item>
<p>Developing new, fast, and cheap diagnostic tools will enable early case detection, thereby enhancing the change of a better therapeutic outcome. Furthermore, these tools might also be able to monitor the therapeutic outcome.</p>
</list-item><list-item>
<p>Especially for the treatment of eumyceotma, new therapeutic options are desperately needed.</p>
</list-item></list>
</sec></boxed-text><boxed-text id="pntd-0002667-box002" position="float"><sec id="s6b">
<title>Top Five Papers</title>
<list list-type="order"><list-item>
<p>Abbott P (1956) Mycetoma in the Sudan. Trans R Soc Trop Med Hyg 50: 11–24; discussion, 24–30.</p>
</list-item><list-item>
<p>Ahmed AO, Mukhtar MM, Kools-Sijmons M, Fahal AH, de Hoog S, et al. (1999) Development of a species-specific PCR-restriction fragment length polymorphism analysis procedure for identification of <italic>Madurella mycetomatis</italic>. J Clin Microbiol 37: 3175–3178.</p>
</list-item><list-item>
<p>van de Sande WWJ, Luijendijk A, Ahmed AO, Bakker-Woudenberg IA, van Belkum A (2005) Testing of the in vitro susceptibilities of <italic>Madurella mycetomatis</italic> to six antifungal agents by using the sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5- [(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay and a modified NCCLS method. Antimicrob Agents Chemother 49: 1364–1368.</p>
</list-item><list-item>
<p>Welsh O, Vera-Cabrera L, Welsh E, Salinas MC (2012) Actinomycetoma and advances in its treatment. Clin Dermatol 30: 372–381.</p>
</list-item><list-item>
<p>Mahgoub ES, Gumaa SA (1984) Ketoconazole in the treatment of eumycetoma due to <italic>Madurella mycetomii</italic>. Trans R Soc Trop Med Hyg 78: 376–379.</p>
</list-item></list>
</sec></boxed-text></sec></body>
<back>
<ack>
<p>The following work, cited in the text above, has been submitted for publication and is currently under review: van de Sande WWJ, Fahal AH, Goodfellow M, Mahgoub el S, Welsh O, et al. The merits and pitfalls of the currently used diagnostic tools in mycetoma. PLOS Negl Trop Dis.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pntd.0002667-WHO1"><label>1</label>
<mixed-citation publication-type="book" xlink:type="simple">WHO (2013) The 17 neglected tropical diseases. Geneva: World Health Organization.</mixed-citation>
</ref>
<ref id="pntd.0002667-Merritt1"><label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Merritt</surname><given-names>RW</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>ED</given-names></name>, <name name-style="western"><surname>Small</surname><given-names>PL</given-names></name>, <name name-style="western"><surname>Wallace</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>PD</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Ecology and transmission of Buruli ulcer disease: a systematic review</article-title>. <source>PLOS Negl Trop Dis</source> <volume>4</volume>: <fpage>e911</fpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-VandeSande1"><label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Van de Sande</surname><given-names>WWJ</given-names></name> (<year>2013</year>) <article-title>Global burden of human mycetoma: a systematic review and meta-analysis</article-title>. <source>PLOS Negl Trop Dis</source> <volume>7</volume>: <fpage>e2550</fpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-QueirozTelles1"><label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Queiroz-Telles</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Nucci</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Colombo</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Tobon</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Restrepo</surname><given-names>A</given-names></name> (<year>2011</year>) <article-title>Mycoses of implantation in Latin America: an overview of epidemiology, clinical manifestations, diagnosis and treatment</article-title>. <source>Med Mycol</source> <volume>49</volume>: <fpage>225</fpage>–<lpage>236</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Ahmed1"><label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ahmed</surname><given-names>AO</given-names></name>, <name name-style="western"><surname>van Leeuwen</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Fahal</surname><given-names>A</given-names></name>, <name name-style="western"><surname>van de Sande</surname><given-names>WWJ</given-names></name>, <name name-style="western"><surname>Verbrugh</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>Mycetoma caused by <italic>Madurella mycetomatis</italic>: a neglected infectious burden</article-title>. <source>Lancet Infect Dis</source> <volume>4</volume>: <fpage>566</fpage>–<lpage>574</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Kaempfer1"><label>6</label>
<mixed-citation publication-type="book" xlink:type="simple">Kaempfer E (1694) Disputatio physica medica inauguralis exhibens decadem observationem exoticarum [phD thesis]. Netherlands: Univeristy of Leiden.</mixed-citation>
</ref>
<ref id="pntd.0002667-Fahal1"><label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fahal</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Sabaa</surname><given-names>AH</given-names></name> (<year>2010</year>) <article-title>Mycetoma in children in Sudan</article-title>. <source>Trans R Soc Trop Med Hyg</source> <volume>104</volume>: <fpage>117</fpage>–<lpage>121</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Abbott1"><label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abbott</surname><given-names>P</given-names></name> (<year>1956</year>) <article-title>Mycetoma in the Sudan</article-title>. <source>Trans R Soc Trop Med Hyg</source> <volume>50</volume>: <fpage>11</fpage>–<lpage>24</lpage> discussion, 24–30.</mixed-citation>
</ref>
<ref id="pntd.0002667-Lynch1"><label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lynch</surname><given-names>JB</given-names></name> (<year>1964</year>) <article-title>Mycetoma in the Sudan</article-title>. <source>Ann R Coll Surg Engl</source> <volume>35</volume>: <fpage>319</fpage>–<lpage>340</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Develoux1"><label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Develoux</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Audoin</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Treguer</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Vetter</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Warter</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>1988</year>) <article-title>Mycetoma in the Republic of Niger: clinical features and epidemiology</article-title>. <source>Am J Trop Med Hyg</source> <volume>38</volume>: <fpage>386</fpage>–<lpage>390</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Bakshi1"><label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bakshi</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Mathur</surname><given-names>DR</given-names></name> (<year>2008</year>) <article-title>Incidence and changing pattern of mycetoma in western Rajasthan</article-title>. <source>Indian J Pathol Microbiol</source> <volume>51</volume>: <fpage>154</fpage>–<lpage>155</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Maiti1"><label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Maiti</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Ray</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bandyopadhyay</surname><given-names>S</given-names></name> (<year>2002</year>) <article-title>Epidemiological aspects of mycetoma from a retrospective study of 264 cases in West Bengal</article-title>. <source>Trop Med Int Health</source> <volume>7</volume>: <fpage>788</fpage>–<lpage>792</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Chakraborti1"><label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chakraborti</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>K</given-names></name> (<year>1998</year>) <article-title>Mycetoma in Chandigarh and surrounding areas</article-title>. <source>Indian J Med Microbiol</source> <volume>16</volume>: <fpage>64</fpage>–<lpage>65</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-LopezMartinez1"><label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lopez Martinez</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Mendez Tovar</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Lavalle</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Welsh</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Saul</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>1992</year>) <article-title>[Epidemiology of mycetoma in Mexico: study of 2105 cases]</article-title>. <source>Gac Med Mex</source> <volume>128</volume>: <fpage>477</fpage>–<lpage>481</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Joshi1"><label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Joshi</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Sanghvi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Vyas</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>JC</given-names></name> (<year>1987</year>) <article-title>Etiology &amp; distribution of mycetoma in Rajasthan, India</article-title>. <source>Indian J Med Res</source> <volume>85</volume>: <fpage>694</fpage>–<lpage>698</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Buot1"><label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Buot</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Lavalle</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Mariat</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Suchil</surname><given-names>P</given-names></name> (<year>1987</year>) <article-title>[Epidemiologic study of mycetomas in Mexico. Apropos of 502 cases]</article-title>. <source>Bull Soc Pathol Exot Filiales</source> <volume>80</volume>: <fpage>329</fpage>–<lpage>339</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Culligan1"><label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Culligan</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>Grant</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Robbs</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Crewe-Brown</surname><given-names>HH</given-names></name> (<year>1985</year>) <article-title>Actinomadura pelletieri mycetoma from the Transvaal. A case report</article-title>. <source>S Afr Med J</source> <volume>68</volume>: <fpage>416</fpage>–<lpage>418</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Freed1"><label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Freed</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Bissett</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Ajello</surname><given-names>L</given-names></name> (<year>1975</year>) <article-title>Actinomycotic mycetoma due to Streptomyces somaliensis: report of a case in South Africa</article-title>. <source>Sabouraudia</source> <volume>13</volume>: <fpage>316</fpage>–<lpage>322</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Vismer1"><label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vismer</surname><given-names>HF</given-names></name>, <name name-style="western"><surname>Morrison</surname><given-names>JG</given-names></name> (<year>1974</year>) <article-title>Mycetoma caused by Actinomadura (Streptomyces) madurae. The first South African case and the results of chemotherapy</article-title>. <source>S Afr Med J</source> <volume>48</volume>: <fpage>433</fpage>–<lpage>437</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Murray1"><label>20</label>
<mixed-citation publication-type="book" xlink:type="simple">Murray IG (1968) Laboratory aspects of mycetoma. In: Wolstenholme GEW, editor. Systemic mycosis. London, WI: J. &amp; A. Churchill Ltd. pp. 78–93.</mixed-citation>
</ref>
<ref id="pntd.0002667-The1"><label>21</label>
<mixed-citation publication-type="other" xlink:type="simple">The Federal Ministry of Health: The National Mycetoma Control Programme (2010) Report on the Epidemiological Study on Mycetoma at El Andalous Village, The White Nile State. Available: <ext-link ext-link-type="uri" xlink:href="http://mycetoma.uofk.edu/news%26events/pdf/AL%20Andalous%20final%20report.pdf" xlink:type="simple">http://mycetoma.uofk.edu/news%26events/pdf/AL%20Andalous%20final%20report.pdf</ext-link>. Accessed 19 February 2014.</mixed-citation>
</ref>
<ref id="pntd.0002667-Porten1"><label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Porten</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sailor</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Comte</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Njikap</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sobry</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Prevalence of Buruli ulcer in Akonolinga health district, Cameroon: results of a cross sectional survey</article-title>. <source>PLOS Negl Trop Dis</source> <volume>3</volume>: <fpage>e466</fpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Phanzu1"><label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Phanzu</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Suykerbuyk</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Imposo</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Lukanu</surname><given-names>PN</given-names></name>, <name name-style="western"><surname>Minuku</surname><given-names>JB</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Effect of a control project on clinical profiles and outcomes in buruli ulcer: a before/after study in Bas-Congo, Democratic Republic of Congo</article-title>. <source>PLOS Negl Trop Dis</source> <volume>5</volume>: <fpage>e1402</fpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-BNNICD1"><label>24</label>
<mixed-citation publication-type="book" xlink:type="simple">BNNICD (2012) Blue Nile Institute for Communicable diseases (BNNICD) newsletter. Wad Medani: Blue Nile Institute for Communicable Diseases. 3 p.</mixed-citation>
</ref>
<ref id="pntd.0002667-Segretain1"><label>25</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Segretain</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Mariat</surname><given-names>F</given-names></name> (<year>1968</year>) <article-title>[Research on the presence of agents of mycetoma in the soil and thorny plants of Senegal and Mauritania]</article-title>. <source>Bull Soc Pathol Exot Filiales</source> <volume>61</volume>: <fpage>194</fpage>–<lpage>202</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Parthasarathi1"><label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Parthasarathi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ranganathan</surname><given-names>LS</given-names></name>, <name name-style="western"><surname>Anandi</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Zeyer</surname><given-names>J</given-names></name> (<year>2007</year>) <article-title>Diversity of microflora in the gut and casts of tropical composting earthworms reared on different substrates</article-title>. <source>J Environ Biol</source> <volume>28</volume>: <fpage>87</fpage>–<lpage>97</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Orchard1"><label>27</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Orchard</surname><given-names>VA</given-names></name>, <name name-style="western"><surname>Goodfellow</surname><given-names>M</given-names></name> (<year>1980</year>) <article-title>Numerical classification of some named strains of <italic>Nocardia asteroides</italic> and related isolates from soil</article-title>. <source>J Gen Microbiol</source> <volume>118</volume>: <fpage>295</fpage>–<lpage>312</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-GonzalezOchoa1"><label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gonzalez-Ochoa</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sandoval</surname><given-names>MA</given-names></name> (<year>1960</year>) <article-title>[Isolation of <italic>Nocardia brasiliensis</italic> and <italic>asteroides</italic> from soils]</article-title>. <source>Rev Inst Salubr Enferm Trop</source> <volume>20</volume>: <fpage>147</fpage>–<lpage>151</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Thirumalachar1"><label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Thirumalachar</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Padhye</surname><given-names>AA</given-names></name> (<year>1968</year>) <article-title>Isolation of <italic>Madurella mycetomi</italic> from soil in India</article-title>. <source>Hindustan Antibiot Bull</source> <volume>10</volume>: <fpage>314</fpage>–<lpage>318</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Sotgiu1"><label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sotgiu</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Mazzoni</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mantovani</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ajello</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Palmer</surname><given-names>J</given-names></name> (<year>1966</year>) <article-title>Survey of soils for human pathogenic fungi from the Emilia-Romagna region of Italy. II. Isolation of <italic>Allescheria boydii</italic>, <italic>Cryptococcus neoformans</italic> and <italic>Histoplasma capsulatum</italic></article-title>. <source>Am J Epidemiol</source> <volume>83</volume>: <fpage>329</fpage>–<lpage>337</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Ajello1"><label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ajello</surname><given-names>L</given-names></name> (<year>1952</year>) <article-title>The isolation of <italic>Aliescheria boydii</italic> shear, an etiologic agent of mycetomas, from soil</article-title>. <source>Am J Trop Med Hyg</source> <volume>1</volume>: <fpage>227</fpage>–<lpage>238</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Ajello2"><label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ajello</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zeidberg</surname><given-names>LD</given-names></name> (<year>1951</year>) <article-title>Isolation of <italic>Histoplasma capsulatum</italic> and <italic>Allescheria boydii</italic> from soil</article-title>. <source>Science</source> <volume>113</volume>: <fpage>662</fpage>–<lpage>663</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Ahmed2"><label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ahmed</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Adelmann</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Fahal</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Verbrugh</surname><given-names>H</given-names></name>, <name name-style="western"><surname>van Belkum</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2002</year>) <article-title>Environmental occurrence of <italic>Madurella mycetomatis</italic>, the major agent of human eumycetoma in Sudan</article-title>. <source>J Clin Microbiol</source> <volume>40</volume>: <fpage>1031</fpage>–<lpage>1036</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-deHoog1"><label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>de Hoog</surname><given-names>GS</given-names></name>, <name name-style="western"><surname>Abdalla Ahmed</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Najafzadeh</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Sutton</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Saradeghi Keisari</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Phylogenetic findings suggest possible new habitat and routes of infection of human eumycetoma</article-title>. <source>PLOS Negl Trop Dis</source> <volume>7</volume>: <fpage>e2229</fpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Fahal2"><label>35</label>
<mixed-citation publication-type="book" xlink:type="simple">Fahal AH (2006) Mycetoma, Clinicopathological Monograph. Khartoum: Khartoum University Press.</mixed-citation>
</ref>
<ref id="pntd.0002667-Findlay1"><label>36</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Findlay</surname><given-names>GH</given-names></name>, <name name-style="western"><surname>Vismer</surname><given-names>HF</given-names></name> (<year>1974</year>) <article-title>Black grain mycetoma. A study of the chemistry, formation and significance of the tissue grain in Madurella mycetomi infection</article-title>. <source>Br J Dermatol</source> <volume>91</volume>: <fpage>297</fpage>–<lpage>303</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Findlay2"><label>37</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Findlay</surname><given-names>GH</given-names></name>, <name name-style="western"><surname>Vismer</surname><given-names>HF</given-names></name> (<year>1977</year>) <article-title>Black grain mycetoma. Atomic absorption and spark source mass spectrophotometry of the tissue grain in Madurella mycetomi infection</article-title>. <source>Br J Dermatol</source> <volume>97</volume>: <fpage>497</fpage>–<lpage>499</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Findlay3"><label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Findlay</surname><given-names>GH</given-names></name>, <name name-style="western"><surname>Vismer</surname><given-names>HF</given-names></name>, <name name-style="western"><surname>Kiebenberg</surname><given-names>NW</given-names></name> (<year>1979</year>) <article-title>Black grain mycetoma: the ultrastructure of Madurella mycetomi</article-title>. <source>Mycopathologia</source> <volume>67</volume>: <fpage>51</fpage>–<lpage>54</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Ibrahim1"><label>39</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ibrahim</surname><given-names>AI</given-names></name>, <name name-style="western"><surname>El Hassan</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Fahal</surname><given-names>A</given-names></name>, <name name-style="western"><surname>van de Sande</surname><given-names>WW</given-names></name> (<year>2013</year>) <article-title>A histopathological exploration of the Madurella mycetomatis grain</article-title>. <source>PLOS One</source> <volume>8</volume>: <fpage>e57774</fpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Mahgoub1"><label>40</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mahgoub</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Gumaa</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>El Hassan</surname><given-names>AM</given-names></name> (<year>1977</year>) <article-title>Immunological status of mycetoma patients</article-title>. <source>Bull Soc Pathol Exot Filiales</source> <volume>70</volume>: <fpage>48</fpage>–<lpage>54</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-vandeSande1"><label>41</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van de Sande</surname><given-names>WW</given-names></name>, <name name-style="western"><surname>Fahal</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Verbrugh</surname><given-names>H</given-names></name>, <name name-style="western"><surname>van Belkum</surname><given-names>A</given-names></name> (<year>2007</year>) <article-title>Polymorphisms in genes involved in innate immunity predispose toward mycetoma susceptibility</article-title>. <source>J Immunol</source> <volume>179</volume>: <fpage>3065</fpage>–<lpage>3074</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Mhmoud1"><label>42</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mhmoud</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Fahal</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Van de Sande</surname><given-names>WWJ</given-names></name> (<year>2013</year>) <article-title>Polymorphisms of interleukin-10 and CCL5 genes in mycetoma</article-title>. <source>Med Mycol</source> <volume>51</volume>: <fpage>527</fpage>–<lpage>533</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-MendezTovar1"><label>43</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mendez-Tovar</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Mondragon-Gonzalez</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Vega-Lopez</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Dockrell</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Hay</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>Cytokine production and lymphocyte proliferation in patients with <italic>Nocardia brasiliensis</italic> actinomycetoma</article-title>. <source>Mycopathologia</source> <volume>158</volume>: <fpage>407</fpage>–<lpage>414</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Cavanagh1"><label>44</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cavanagh</surname><given-names>LL</given-names></name> (<year>1974</year>) <article-title>Attempts to induce mycetoma in monkeys and mice using <italic>Madurella mycetomi</italic></article-title>. <source>Sabouraudia</source> <volume>12</volume>: <fpage>258</fpage>–<lpage>262</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Ahmed3"><label>45</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ahmed</surname><given-names>AO</given-names></name>, <name name-style="western"><surname>van Vianen</surname><given-names>W</given-names></name>, <name name-style="western"><surname>ten Kate</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>van de Sande</surname><given-names>WW</given-names></name>, <name name-style="western"><surname>van Belkum</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>A murine model of <italic>Madurella mycetomatis</italic> eumycetoma</article-title>. <source>FEMS Immunol Med Microbiol</source> <volume>37</volume>: <fpage>29</fpage>–<lpage>36</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Mahgoub2"><label>46</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mahgoub</surname><given-names>ES</given-names></name> (<year>1978</year>) <article-title>Experimental infection of athymic nude New Zealand mice, nu nu strain with mycetoma agents</article-title>. <source>Sabouraudia</source> <volume>16</volume>: <fpage>211</fpage>–<lpage>216</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-vanHellemond1"><label>47</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van Hellemond</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Vonk</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>de Vogel</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Koelewijn</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Vaessen</surname><given-names>N</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Association of eumycetoma and schistosomiasis</article-title>. <source>PLOS Negl Trop Dis</source> <volume>7</volume>: <fpage>e2241</fpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Prentice1"><label>48</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Prentice</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Rahalison</surname><given-names>L</given-names></name> (<year>2007</year>) <article-title>Plague</article-title>. <source>Lancet</source> <volume>369</volume>: <fpage>1196</fpage>–<lpage>1207</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Gryseels1"><label>49</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gryseels</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Polman</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Clerinx</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kestens</surname><given-names>L</given-names></name> (<year>2006</year>) <article-title>Human schistosomiasis</article-title>. <source>Lancet</source> <volume>368</volume>: <fpage>1106</fpage>–<lpage>1118</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Radolf1"><label>50</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Radolf</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Caimano</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Stevenson</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>LT</given-names></name> (<year>2012</year>) <article-title>Of ticks, mice and men: understanding the dual-host lifestyle of Lyme disease spirochaetes</article-title>. <source>Nat Rev Microbiol</source> <volume>10</volume>: <fpage>87</fpage>–<lpage>99</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Kweku1"><label>51</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kweku</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Odoom</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Puplampu</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Desewu</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Nuako</surname><given-names>GK</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>An outbreak of suspected cutaneous leishmaniasis in Ghana: lessons learnt and preparation for future outbreaks</article-title>. <source>Glob Health Action</source> <volume>4</volume> <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3402/gha.v4i0.5527" xlink:type="simple">10.3402/gha.v4i0.5527</ext-link></comment></mixed-citation>
</ref>
<ref id="pntd.0002667-Zhang1"><label>52</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>MacArthur</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mubila</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Baker</surname><given-names>S</given-names></name> (<year>2010</year>) <article-title>Control of neglected tropical diseases needs a long-term commitment</article-title>. <source>BMC Med</source> <volume>8</volume>: <fpage>67</fpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Curtis1"><label>53</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Curtis</surname><given-names>CF</given-names></name>, <name name-style="western"><surname>Maxwell</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Magesa</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Rwegoshora</surname><given-names>RT</given-names></name>, <name name-style="western"><surname>Wilkes</surname><given-names>TJ</given-names></name> (<year>2006</year>) <article-title>Insecticide-treated bed-nets for malaria mosquito control</article-title>. <source>J Am Mosq Control Assoc</source> <volume>22</volume>: <fpage>501</fpage>–<lpage>506</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Mhmoud2"><label>54</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mhmoud</surname><given-names>NA</given-names></name>, <name name-style="western"><surname>Ahmed</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Fahal</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>de Hoog</surname><given-names>GS</given-names></name>, <name name-style="western"><surname>Gerrits van den Ende</surname><given-names>AH</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title><italic>Pleurostomophora ochracea</italic>, a novel agent of human eumycetoma with yellow grains</article-title>. <source>J Clin Microbiol</source> <volume>50</volume>: <fpage>2987</fpage>–<lpage>2994</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Ahmed4"><label>55</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ahmed</surname><given-names>AO</given-names></name>, <name name-style="western"><surname>Mukhtar</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Kools-Sijmons</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fahal</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>de Hoog</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>1999</year>) <article-title>Development of a species-specific PCR-restriction fragment length polymorphism analysis procedure for identification of <italic>Madurella mycetomatis</italic></article-title>. <source>J Clin Microbiol</source> <volume>37</volume>: <fpage>3175</fpage>–<lpage>3178</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Quintana1"><label>56</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Quintana</surname><given-names>ET</given-names></name>, <name name-style="western"><surname>Wierzbicka</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Mackiewicz</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Osman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fahal</surname><given-names>AH</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title><italic>Streptomyces sudanensis</italic> sp. nov., a new pathogen isolated from patients with actinomycetoma</article-title>. <source>Antonie Van Leeuwenhoek</source> <volume>93</volume>: <fpage>305</fpage>–<lpage>313</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Namangala1"><label>57</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Namangala</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Hachaambwa</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Kajino</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Mweene</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Hayashida</surname><given-names>K</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>The use of Loop-mediated Isothermal Amplification (LAMP) to detect the re-emerging Human African Trypanosomiasis (HAT) in the Luangwa and Zambezi valleys</article-title>. <source>Parasit Vectors</source> <volume>5</volume>: <fpage>282</fpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Matovu1"><label>58</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Matovu</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Kuepfer</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Boobo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kibona</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Burri</surname><given-names>C</given-names></name> (<year>2010</year>) <article-title>Comparative detection of trypanosomal DNA by loop-mediated isothermal amplification and PCR from flinders technology associates cards spotted with patient blood</article-title>. <source>J Clin Microbiol</source> <volume>48</volume>: <fpage>2087</fpage>–<lpage>2090</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Surabattula1"><label>59</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Surabattula</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Vejandla</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Mallepaddi</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Faulstich</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Polavarapu</surname><given-names>R</given-names></name> (<year>2013</year>) <article-title>Simple, rapid, inexpensive platform for the diagnosis of malaria by loop mediated isothermal amplification (LAMP)</article-title>. <source>Exp Parasitol</source> <volume>134</volume>: <fpage>333</fpage>–<lpage>340</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Verma1"><label>60</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Verma</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Avishek</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Negi</surname><given-names>NS</given-names></name>, <name name-style="western"><surname>Ramesh</surname><given-names>V</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Application of loop-mediated isothermal amplification assay for the sensitive and rapid diagnosis of visceral leishmaniasis and post-kala-azar dermal leishmaniasis</article-title>. <source>Diagn Microbiol Infect Dis</source> <volume>75</volume>: <fpage>390</fpage>–<lpage>395</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Ablordey1"><label>61</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ablordey</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Amissah</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Aboagye</surname><given-names>IF</given-names></name>, <name name-style="western"><surname>Hatano</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Yamazaki</surname><given-names>T</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Detection of <italic>Mycobacterium ulcerans</italic> by the loop mediated isothermal amplification method</article-title>. <source>PLOS Negl Trop Dis</source> <volume>6</volume>: <fpage>e1590</fpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Akhoundi1"><label>62</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Akhoundi</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Mohebali</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shojaee</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jalali</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kazemi</surname><given-names>B</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Rapid detection of human and canine visceral leishmaniasis: assessment of a latex agglutination test based on the A2 antigen from amastigote forms of <italic>Leishmania infantum</italic></article-title>. <source>Exp Parasitol</source> <volume>133</volume>: <fpage>307</fpage>–<lpage>313</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-SilveiraGomes1"><label>63</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Silveira-Gomes</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Sarmento</surname><given-names>DN</given-names></name>, <name name-style="western"><surname>Pinto</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Pimentel</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Nepomuceno</surname><given-names>LB</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Development and evaluation of a latex agglutination test for the serodiagnosis of paracoccidioidomycosis</article-title>. <source>Clin Vaccine Immunol</source> <volume>18</volume>: <fpage>604</fpage>–<lpage>608</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Attar1"><label>64</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Attar</surname><given-names>ZJ</given-names></name>, <name name-style="western"><surname>Chance</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>el-Safi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Carney</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Azazy</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>Latex agglutination test for the detection of urinary antigens in visceral leishmaniasis</article-title>. <source>Acta Trop</source> <volume>78</volume>: <fpage>11</fpage>–<lpage>16</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Darani1"><label>65</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Darani</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Ahmadi</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Zabardast</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Yousefi</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Shirzad</surname><given-names>H</given-names></name> (<year>2010</year>) <article-title>Development of a Latex Agglutination Test as a Simple and Rapid Method for Diagnosis of <italic>Trichomonas vaginalis</italic> Infection</article-title>. <source>Avicenna J Med Biotechnol</source> <volume>2</volume>: <fpage>63</fpage>–<lpage>66</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Welsh1"><label>66</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Welsh</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Vera-Cabrera</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Welsh</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Salinas</surname><given-names>MC</given-names></name> (<year>2012</year>) <article-title>Actinomycetoma and advances in its treatment</article-title>. <source>Clin Dermatol</source> <volume>30</volume>: <fpage>372</fpage>–<lpage>381</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Zein1"><label>67</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zein</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Fahal</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Mahgoub el</surname><given-names>S</given-names></name>, <name name-style="western"><surname>El Hassan</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Abdel-Rahman</surname><given-names>ME</given-names></name> (<year>2012</year>) <article-title>Predictors of cure, amputation and follow-up dropout among patients with mycetoma seen at the Mycetoma Research Centre, University of Khartoum, Sudan</article-title>. <source>Trans R Soc Trop Med Hyg</source> <volume>106</volume>: <fpage>639</fpage>–<lpage>644</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Mahgoub3"><label>68</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mahgoub</surname><given-names>ES</given-names></name> (<year>1976</year>) <article-title>Medical management of mycetoma</article-title>. <source>Bull World Health Organ</source> <volume>54</volume>: <fpage>303</fpage>–<lpage>310</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Findor1"><label>69</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Findor</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Sorda</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Igartua</surname><given-names>EB</given-names></name>, <name name-style="western"><surname>Avagnina</surname><given-names>A</given-names></name> (<year>1998</year>) <article-title>Ketoconazole-induced liver damage</article-title>. <source>Medicina (B Aires)</source> <volume>58</volume>: <fpage>277</fpage>–<lpage>281</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Bernuau1"><label>70</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bernuau</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Durand</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Pessayre</surname><given-names>D</given-names></name> (<year>1997</year>) <article-title>Ketoconazole-induced hepatotoxicity</article-title>. <source>Hepatology</source> <volume>26</volume>: <fpage>802</fpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-vandeSande2"><label>71</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van de Sande</surname><given-names>WWJ</given-names></name>, <name name-style="western"><surname>Fahal</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Bakker-Woudenberg</surname><given-names>IAJM</given-names></name>, <name name-style="western"><surname>van Belkum</surname><given-names>A</given-names></name> (<year>2010</year>) <article-title><italic>Madurella mycetomatis</italic> is not susceptible to the echinocandin class of antifungal agents</article-title>. <source>Antimicrob Agents Chemother</source> <volume>54</volume>: <fpage>2738</fpage>–<lpage>2740</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-vandeSande3"><label>72</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van de Sande</surname><given-names>WWJ</given-names></name>, <name name-style="western"><surname>Luijendijk</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ahmed</surname><given-names>AO</given-names></name>, <name name-style="western"><surname>Bakker-Woudenberg</surname><given-names>IA</given-names></name>, <name name-style="western"><surname>van Belkum</surname><given-names>A</given-names></name> (<year>2005</year>) <article-title>Testing of the in vitro susceptibilities of <italic>Madurella mycetomatis</italic> to six antifungal agents by using the sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5- [(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay and a modified NCCLS method</article-title>. <source>Antimicrob Agents Chemother</source> <volume>49</volume>: <fpage>1364</fpage>–<lpage>1368</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Kloezen1"><label>73</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kloezen</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Meis</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Curfs-Breuker</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Fahal</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Van de Sande</surname><given-names>WWJ</given-names></name> (<year>2012</year>) <article-title>In vitro antifungal activity of isavuconazole to <italic>Madurella mycetomatis</italic></article-title>. <source>Antimicrob Agents Chemother</source> <volume>56</volume>: <fpage>6054</fpage>–<lpage>6056</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-vanBelkum1"><label>74</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van Belkum</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fahal</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>van de Sande</surname><given-names>WW</given-names></name> (<year>2011</year>) <article-title>In vitro susceptibility of <italic>Madurella mycetomatis</italic> to posaconazole and terbinafine</article-title>. <source>Antimicrob Agents Chemother</source> <volume>55</volume>: <fpage>1771</fpage>–<lpage>1773</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Ahmed5"><label>75</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ahmed</surname><given-names>AO</given-names></name>, <name name-style="western"><surname>van de Sande</surname><given-names>WWJ</given-names></name>, <name name-style="western"><surname>van Vianen</surname><given-names>W</given-names></name>, <name name-style="western"><surname>van Belkum</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fahal</surname><given-names>AH</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title><italic>In vitro</italic> susceptibilities of <italic>Madurella mycetomatis</italic> to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay</article-title>. <source>Antimicrob Agents Chemother</source> <volume>48</volume>: <fpage>2742</fpage>–<lpage>2746</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Mahgoub4"><label>76</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mahgoub</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Gumaa</surname><given-names>SA</given-names></name> (<year>1984</year>) <article-title>Ketoconazole in the treatment of eumycetoma due to <italic>Madurella mycetomii</italic></article-title>. <source>Trans R Soc Trop Med Hyg</source> <volume>78</volume>: <fpage>376</fpage>–<lpage>379</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Fahal3"><label>77</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fahal</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Rahman</surname><given-names>IA</given-names></name>, <name name-style="western"><surname>El-Hassan</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Rahman</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Zijlstra</surname><given-names>EE</given-names></name> (<year>2011</year>) <article-title>The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to <italic>Madurella mycetomatis</italic></article-title>. <source>Trans R Soc Trop Med Hyg</source> <volume>105</volume>: <fpage>127</fpage>–<lpage>132</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Negroni1"><label>78</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Negroni</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Tobon</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bustamante</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Shikanai-Yasuda</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Patino</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Posaconazole treatment of refractory eumycetoma and chromoblastomycosis</article-title>. <source>Rev Inst Med Trop Sao Paulo</source> <volume>47</volume>: <fpage>339</fpage>–<lpage>346</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Lacroix1"><label>79</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lacroix</surname><given-names>C</given-names></name>, <name name-style="western"><surname>de Kerviler</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Morel</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Derouin</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Feuilhade de Chavin</surname><given-names>M</given-names></name> (<year>2005</year>) <article-title><italic>Madurella mycetomatis</italic> mycetoma treated successfully with oral voriconazole</article-title>. <source>Br J Dermatol</source> <volume>152</volume>: <fpage>1067</fpage>–<lpage>1068</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Loulergue1"><label>80</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Loulergue</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Hot</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Dannaoui</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Dallot</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Poiree</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Successful treatment of black-grain mycetoma with voriconazole</article-title>. <source>Am J Trop Med Hyg</source> <volume>75</volume>: <fpage>1106</fpage>–<lpage>1107</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Porte1"><label>81</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Porte</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Khatibi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hajj</surname><given-names>LE</given-names></name>, <name name-style="western"><surname>Cassaing</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Berry</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title><italic>Scedosporium apiospermum</italic> mycetoma with bone involvement successfully treated with voriconazole</article-title>. <source>Trans R Soc Trop Med Hyg</source> <volume>100</volume>: <fpage>891</fpage>–<lpage>894</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Schaenman1"><label>82</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schaenman</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Digiulio</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Mirels</surname><given-names>LF</given-names></name>, <name name-style="western"><surname>McClenny</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Berry</surname><given-names>GJ</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title><italic>Scedosporium apiospermum</italic> soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy</article-title>. <source>J Clin Microbiol</source> <volume>43</volume>: <fpage>973</fpage>–<lpage>977</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-NDiaye1"><label>83</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>N'Diaye</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Dieng</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Perez</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Stockmeyer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bakshi</surname><given-names>R</given-names></name> (<year>2006</year>) <article-title>Clinical efficacy and safety of oral terbinafine in fungal mycetoma</article-title>. <source>Int J Dermatol</source> <volume>45</volume>: <fpage>154</fpage>–<lpage>157</lpage>.</mixed-citation>
</ref>
<ref id="pntd.0002667-Ahmed6"><label>84</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ahmed</surname><given-names>AO</given-names></name>, <name name-style="western"><surname>Abugroun</surname><given-names>ES</given-names></name> (<year>1998</year>) <article-title>Unexpected high prevalence of secondary bacterial infection in patients with mycetoma</article-title>. <source>J Clin Microbiol</source> <volume>36</volume>: <fpage>850</fpage>–<lpage>851</lpage>.</mixed-citation>
</ref>
</ref-list></back>
</article>